Treatment of posttransplant lymphoproliferative disease with rituximab: The remission, the relapse, and the complication

Transplantation

Volumn 73, Issue 1, 2002, Pages 100-104

  Verschuuren, Erik A M ^a   Stevens, Servi J C ^b   Van Imhoff, Gustaaf W ^a   Middeldorp, Jaap M ^b   De Boer, Conny ^a   Koëter, Gerard ^a   The, T Hauw ^a   Van Der Bij, Wim ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOSPORIN; CYCLOSPORIN A; GANCICLOVIR; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VALACICLOVIR; VIRUS DNA;

ADULT; ARTICLE; ASPERGILLOSIS; B LYMPHOCYTE; BRONCHIOLITIS; CASE REPORT; CAUSE OF DEATH; CELL COUNT; DISEASE COURSE; DRUG EFFICACY; EPSTEIN BARR VIRUS; FEMALE; FLOW CYTOMETRY; HUMAN; HYPOGAMMAGLOBULINEMIA; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; REMISSION; VIRUS LOAD;

EID: 0037080795     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200201150-00019     Document Type: Article

References (21)

1. A novel form of Epstein-Barr virus latency in normal B cells in vivo
2. Epstein-Barr virus replication in oropharyngeal epithelial cells
3. Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. I. Specificity and HLA restriction of effector cells reactivated in vitro
4. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
5. Epstein-Barr virus
6. The Registry of the International Society for Heart and Lung Transplantation: Tenth official report-1993
7. Epstein-Barr virus-induced post-transplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting
8. The diagnosis and treatment of posttransplant lymphoproliferative disorders
9. Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single center
10. Humanized anti-CD20 monoclonal antibody (Rituximab) in posttransplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
11. Treatment of central nervous system B lymphoproliferative syndrome by local infusion of a B cell-specific monoclonal antibody
12. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome
13. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation
14. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation
15. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation
16. Monitoring antigenemia is useful in guiding treatment of severe cytomegalovirus disease after organ transplantation
17. Monitoring of Epstein-Barr virus DNA load in peripheral blood by quantitative competitive PCR
18. CD20-negative relapse in B-cell lymphoma after treatment with Rituximab
19. Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders
20. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
21. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients